Aadi Bioscience, Inc.
Aadi Bioscience, Inc. (AADI) Stock Ownership
Institutional vs insider vs public ownership from 13F and float data — top holders, activity, and insider trades below.
SEC 13F · FMP · AADI · as of Sep 30, 2025
Ownership Breakdown
39
Institutional Holders
▲ 1 vs Q2
$54.34M
Total Inst. Value
▼ $267,501 vs Q2
46.29M
Shares Outstanding
freeFloat 17.95%
28.83M
13F Shares Held
▼ 601,766 vs Q2
Institutional ownership = 13F shares ÷ total outstanding. Insider % = 100 − free float. Public % = free float − institution %. Data: FMP /symbol-positions-summary + /shares-float + SEC EDGAR.
Top Institutional Holders
AADI largest shareholders · institutional ownership
Q3 2025 · SEC 13F
Showing top 10 holders
| Holder | Shares | % Owned | Weight | Value | Reported | Change |
|---|---|---|---|---|---|---|
QVT FINANCIAL LP pharmaceutical preparations | 4.62M | 6.67% | 6.67% | $8.33B | Nov 14, 2025 | — held |
ORBIMED ADVISORS LLC pharmaceutical preparations | 4.17M | 6.02% | 6.02% | $7.92B | Nov 14, 2025 | — held |
SUVRETTA CAPITAL MANAGEMENT, LLC pharmaceutical preparations | 3.70M | 5.35% | 5.35% | $7.03B | Nov 14, 2025 | — held |
ACUTA CAPITAL PARTNERS, LLC pharmaceutical preparations | 3.41M | 4.93% | 4.93% | $6.48B | Nov 14, 2025 | — held |
AVORO CAPITAL ADVISORS LLC pharmaceutical preparations | 2.85M | 4.12% | 4.12% | $5.41B | Nov 14, 2025 | — held |
SIREN, L.L.C. pharmaceutical preparations | 2.08M | 3.01% | 3.01% | $3.96B | Nov 13, 2025 | — held |
YU FAN pharmaceutical preparations | 2.07M | 2.99% | 2.99% | $3.93B | Nov 14, 2025 | — held |
VANGUARD GROUP INC pharmaceutical preparations | 1.34M | 1.94% | 1.94% | $2.55B | Nov 7, 2025 | ▲ 27.6K |
ACORN CAPITAL ADVISORS, LLC pharmaceutical preparations | 1.14M | 1.65% | 1.65% | $2.16B | Nov 17, 2025 | — held |
ALLY BRIDGE GROUP (NY) LLC pharmaceutical preparations | 817.9K | 1.18% | 1.18% | $1.55B | Nov 14, 2025 | — held |
Data from SEC Form 13F filings. Ownership bar normalised to largest holder. Change flags: isNew / isSoldOut / changeInSharesNumber (FMP extract-analytics/holder).
Institutional Activity
Q3 2025 vs prior quarter
Q3 2025
6
Increased
+267.6K shares3
New Positions
first time holders10
Decreased
−236.6K shares3
Sold Out
fully exitedNet shares change (top 50)
+31.0K
+267.6K / −236.6K
Net new holders
-4
3 new / 3 exited
Based on top 50 institutional holders by position size. Fields: isNew, isSoldOut, changeInSharesNumber (FMP extract-analytics/holder, limit=50).
Insider Buying vs Selling
AADI insider trading · insider activity
Source: SEC Form 4
Insiders have been primarily selling shares recently. Selling may be driven by pre-scheduled Rule 10b5-1 plans rather than negative sentiment.
9
Buy transactions
6
Sell transactions
1.50
Buy/Sell ratio
$0M
Total disposed
Recent Insider Transactions
Showing 10 most recent · Common Stock only
| Name · Role | Date | Type | Shares | Price | Value | After Trans. | Filing |
|---|---|---|---|---|---|---|---|
Dalal Anupam director | Mar 4, 2025 | Award | 1,561,000 | $2.40 | $3.75M | 3.41M | Form 4 ↗ |
Castelein Caley director | Mar 4, 2025 | Award | 1,666,000 | $2.40 | $4.00M | 2.17M | Form 4 ↗ |
Zhao Baiteng director | Mar 4, 2025 | Award | 1,250,000 | $2.40 | $3.00M | 1.25M | Form 4 ↗ |
Dornan David Chief Scientific Officer | Mar 4, 2025 | Award | 687,979 | $2.31 | $1.59M | 688.0K | Form 4 ↗ |
BALL BRYAN See remarks | Mar 4, 2025 | Award | 100,000 | $2.40 | $240.0K | 202.9K | Form 4 ↗ |
BALL BRYAN See remarks | Mar 3, 2025 | Sale | 2,147 | $2.35 | $5.0K | 102.9K | Form 4 ↗ |
Aghazadeh Behzad See Remarks | Feb 28, 2025 | Award | 8,333,000 | $0.00 | $833.3 | 8.33M | Form 4 ↗ |
Giacobello Scott M. CHIEF FINANCIAL OFFICER | Mar 3, 2025 | Sale | 2,806 | $2.35 | $6.6K | 23.9K | Form 4 ↗ |
Lennon David James CHIEF EXECUTIVE OFFICER | Mar 3, 2025 | Sale | 5,690 | $2.35 | $13.4K | 33.4K | Form 4 ↗ |
Zhao Baiteng director | Dec 19, 2024 | Award | 61,192 | $2.32 | $142.0K | 61.2K | Form 4 ↗ |
Source: /insider-trading/search (FMP stable). Buy/Sell direction: acquisitionOrDisposition A=Buy, D=Sell. RSU vesting (M-Exempt) excluded from sentiment bar. All data from SEC EDGAR public filings.
About institutional & insider ownership
Aadi Bioscience, Inc. (AADI) is primarily owned by institutional investors, who hold approximately 62.3% of total shares outstanding. Company insiders own approximately 82.05%, while retail and public investors account for the remaining 0.00%.
The largest institutional shareholder of Aadi Bioscience, Inc. is QVT FINANCIAL LP, holding approximately 4.62 million shares — equal to 6.67% of outstanding shares — as of September 30, 2025.
A total of 39 institutional investors currently hold AADI stock, with a combined institutional value of approximately $54,340,996 as of the most recent 13F filing period.
Frequently asked questions
AADI ownershipAadi Bioscience, Inc. (AADI) is primarily owned by institutional investors, who hold approximately 62.3% of shares. The largest shareholder is QVT FINANCIAL LP with a 6.67% stake. Company insiders hold 82.05%. Data sourced from SEC Form 13F as of September 30, 2025.